Summit Therapeutics Inc.
SMMT
$26.20
$0.190.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 870.38% | 84.34% | 98.76% | 118.11% | 60.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 113.29% | 114.15% | 105.89% | 104.35% | 93.79% |
| Total Operating Expenses | 428.37% | 104.95% | 137.78% | 176.72% | 130.70% |
| Operating Income | -428.37% | -104.95% | -137.78% | -176.72% | -131.52% |
| Income Before Tax | -361.42% | -107.50% | 64.01% | 67.09% | 72.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -361.42% | -107.50% | 64.01% | 67.09% | 72.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -361.42% | -107.50% | 64.01% | 67.09% | 72.95% |
| EBIT | -428.37% | -104.95% | -137.78% | -176.72% | -131.52% |
| EBITDA | -428.70% | -105.11% | -138.21% | -178.58% | -134.18% |
| EPS Basic | -338.19% | -99.70% | 80.00% | 82.21% | 86.23% |
| Normalized Basic EPS | -382.53% | -86.97% | -78.39% | -67.86% | 21.43% |
| EPS Diluted | -335.38% | -110.98% | 79.10% | 81.76% | 85.96% |
| Normalized Diluted EPS | -382.53% | -86.97% | -78.39% | -67.86% | 21.43% |
| Average Basic Shares Outstanding | 4.87% | 4.01% | 16.15% | 38.50% | 87.31% |
| Average Diluted Shares Outstanding | 4.87% | 4.01% | 16.15% | 38.50% | 87.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |